[Progress in targeted therapy for chronic thromboembolic pulmonary hypertension]

Chronic thromboembolic pulmonary hypertension (CTEPH) is a pulmonary vascular disease characterized by organized thrombotic obstruction of the pulmonary arteries and subsequent pulmonary vascular remodeling. The therapeutic strategy has evolved from a solely surgical approach to a comprehensive system incorporating pulmonary endarterectomy, balloon pulmonary angioplasty and targeted drugs. Although riociguat remains the only drug formally approved for patients with inoperable or residual/recurrent pulmonary hypertension in China, accumulating evidence suggests that other targeted agents, such as treprostinil, may also show clinical benefits in CTEPH. Current evidence highlights the importance of multimodal therapy. This review aims to comprehensively summarize recent advances in targeted drugs for CTEPH patients and to examine the current applications and unresolved challenges associated with multimodal therapy strategies in this field.